TriangleHEALTH PROFESSIONAL · SOURCE READING
Temozolomide
Source: Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Temozolomide, an oral alkylating agent, appeared to be similar to IV dacarbazine in a randomized phase III trial with a primary end point of OS. However, because the trial was designed to demonstrate the superiority of temozolomide, which was not achieved, the trial was left with a sample size that was inadequate to provide statistical proof of noninferiority.[34]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice